MARLBOROUGH, Mass.,
June 2, 2016 /PRNewswire/
-- Hologic, Inc. (NASDAQ: HOLX) announced today that nine-time
Grammy award-winning singer, songwriter and breast cancer survivor
Sheryl Crow will serve as national
spokesperson to educate women about a more accurate mammogram, the
Genius™ 3D MAMMOGRAPHY™ exam. The Genius™ exam is the only
mammogram proven to reduce unnecessary callbacks by up to 40
percent, and detect 41 percent more invasive cancers than
conventional mammography alone.[1],[2]
One in every eight women will develop breast cancer in her
lifetime, but if caught early, the five-year survival rate is
nearly 100 percent.[3],[4] Crow, a breast cancer
survivor marking 10 years since her diagnosis, understands the
critical importance of early detection and is committed to ensuring
women across the country are educated on the life-saving
technologies available to them.
"Early detection saves lives — it's that simple," said Crow.
"Women need to be advocates for their health, and that means
getting annual mammograms starting at age 40 and taking advantage
of the best, and most accurate, technologies available. I opted for
a Genius™ exam because early detection is what saved my life — it's
a woman's best chance at survival, and it's a chance we all
deserve."
In April, Hologic launched a national campaign, the Better
Mammogram Poll, educating women about the benefits of the Genius™
3D MAMMOGRAPHY™ exam — which is proven to detect cancer 15 months
earlier than traditional 2D screenings — as well as providing women
with tools to easily find local facilities offering the Genius™
exam.[5] Crow will be an integral part of the campaign,
educating women through various media efforts, including a
satellite media tour and social media outreach. The campaign will
continue through Breast Cancer Awareness Month 2016.
"It's an honor to join forces with such a well-known artist and
breast cancer survivor days before National Cancer Survivors Day,"
said Pete Valenti, Hologic's
Division President, Breast and Skeletal Health Solutions. "We
remain resolute in our commitment to developing innovative new
technologies, like the Genius™ exam, which detects more invasive
cancers than conventional mammography, improving a woman's chance
of survival. We look forward to working with Sheryl as we continue
to spread the message that early detection saves lives."
As part of the Company's commitment to helping people survive
cancer, Hologic will donate $30,000
to Stand Up To Cancer, a program of the Entertainment Industry
Foundation focused on raising funds to accelerate the pace of
research to get new therapies to patients quickly and save lives
now. The donation is part of the Company's larger pledge to make 30
donations of up to $30,000 each
during its 30th anniversary year to select non-profit
organizations focused on education and healthcare.
The Genius™ 3D MAMMOGRAPHY™ exam is FDA-approved and available
on the Hologic Selenia® Dimensions® system.
Additional information, as well as a locator to find imaging sites
offering Genius™ 3D MAMMOGRAPHY™ exams, can be found at
http://mygenius3d.com/.
About Hologic
Hologic, Inc. is a leading developer,
manufacturer and supplier of premium diagnostic products, medical
imaging systems and surgical products. The Company's core business
units focus on diagnostics, breast health, GYN surgical and
skeletal health. With a unified suite of technologies and a robust
research and development program, Hologic is dedicated to The
Science of Sure. For more information on Hologic, visit
www.hologic.com.
Hologic, 3D Mammography, Dimensions, Genius, Selenia and the
Science of Sure are trademarks and/or registered trademarks of
Hologic, Inc., and/or its subsidiaries in the United States and/or other countries.
Forward-Looking Statements
This news release may
contain forward-looking information that involves risks and
uncertainties, including statements about the use of Hologic
mammography systems. There can be no assurance the systems will
achieve the benefits described here, or that such benefits will be
replicated in any particular manner with respect to an individual
patient. The actual effect of the use of the systems can only be
determined on a case-by-case basis depending on the particular
circumstances and patient in question. In addition, there can be no
assurance that the systems will achieve any expected level of sales
or market share. Hologic expressly disclaims any obligation to
release publicly any updates to the data or statements presented
here to reflect any change in the Company's expectations or any
change in events, conditions or circumstances on which any such
data or statements are based.
Media Contact:
Jane
Mazur
508.263.8764 (direct)
585.355.5978 (mobile)
jane.mazur@hologic.com
Investor Contact:
Michael
Watts
858.410.8588
michael.watts@hologic.com
[1] Friedewald SM, Rafferty EA, Rose SL, et al. Breast cancer
screening using tomosynthesis in combination with digital
mammography. JAMA. 2014;311(24):2499-2507.
[2] Rose SL, Tidwell AL, Bujnoch LJ, et al. Implementation of
breast tomosynthesis in a routine screening practice: an
observational study. AJR Am J Roentgenol.
2013;200(6):1401-1408.
[3] National Breast Cancer Foundation, Inc. Stages 0 & 1:
what does is mean to have stage 1 breast cancer? National Breast
Cancer Foundation, Inc.
http://www.nationalbreastcancer.org/breast-cancer-facts. Accessed
on: March 31, 2015.
[4] Breastcancer.org. US breast cancer statistics.
Breastcancer.org.
http://www.breastcancer.org/symptoms/understand_bc/statistics.
Accessed on: May 25, 2016.
[5] McDonald ES, Oustimov A, Weinstein SP, et al. Effectiveness
of Digital Breast Tomosynthesis Compared With Digital Mammography.
JAMA Oncol. 2016.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/sheryl-crow-named-hologics-national-celebrity-spokesperson-for-new-breast-cancer-educational-campaign-300278277.html
SOURCE Hologic, Inc.